MX2023013064A - Terapias combinadas que comprenden inhibidores de shp2 e inhibidores de pd-1. - Google Patents
Terapias combinadas que comprenden inhibidores de shp2 e inhibidores de pd-1.Info
- Publication number
- MX2023013064A MX2023013064A MX2023013064A MX2023013064A MX2023013064A MX 2023013064 A MX2023013064 A MX 2023013064A MX 2023013064 A MX2023013064 A MX 2023013064A MX 2023013064 A MX2023013064 A MX 2023013064A MX 2023013064 A MX2023013064 A MX 2023013064A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- shp2
- combination therapies
- inhibitor
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184685P | 2021-05-05 | 2021-05-05 | |
| US202263320997P | 2022-03-17 | 2022-03-17 | |
| PCT/US2022/027696 WO2022235817A1 (en) | 2021-05-05 | 2022-05-04 | Combination therapies comprising shp2 inhibitors and pd-1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013064A true MX2023013064A (es) | 2023-11-15 |
Family
ID=83932910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013064A MX2023013064A (es) | 2021-05-05 | 2022-05-04 | Terapias combinadas que comprenden inhibidores de shp2 e inhibidores de pd-1. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12097203B2 (https=) |
| EP (1) | EP4334318A4 (https=) |
| JP (1) | JP2024516037A (https=) |
| AU (1) | AU2022271243A1 (https=) |
| CA (1) | CA3217084A1 (https=) |
| IL (1) | IL308222A (https=) |
| MX (1) | MX2023013064A (https=) |
| WO (1) | WO2022235817A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023012929A (es) * | 2021-05-05 | 2023-11-13 | Huyabio Int Llc | Terapias de combinacion que comprenden inhibidores de shp2 e inhibidores de tirosina cinasa egfr. |
| AU2023385809A1 (en) * | 2022-11-23 | 2025-05-29 | Huyabio International, Llc | Combination therapies comprising KRAS inhibitors and SHP2 inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| US10287266B2 (en) | 2015-06-19 | 2019-05-14 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
| WO2017210134A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
| MX388576B (es) | 2016-06-07 | 2025-03-20 | Jacobio Pharmaceuticals Co Ltd | Derivados heterociclicos novedosos utiles como inhibidores de shp2. |
| WO2017216706A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| EP4302834A3 (en) | 2016-07-12 | 2024-07-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| CA3048340A1 (en) | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
| EA202190196A1 (ru) | 2017-03-23 | 2021-08-31 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| TW201930292A (zh) | 2017-10-12 | 2019-08-01 | 美商銳新醫藥公司 | 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物 |
| US11110171B2 (en) * | 2017-12-21 | 2021-09-07 | New York University | PD-1 related cancer therapy |
| WO2019152454A1 (en) | 2018-01-30 | 2019-08-08 | Research Development Foundation | Shp2 inhibitors and methods of use thereof |
| RU2020133727A (ru) | 2018-03-21 | 2022-04-21 | Сучжоу Пухе Биофарма Ко., Лтд. | Ингибиторы shp2 и их применение |
| MX2020010719A (es) | 2018-04-10 | 2020-11-06 | Revolution Medicines Inc | Composiciones de inhibidores de shp2, metodos para tratar el cancer y metodos para identificar a un sujeto con mutaciones en shp2. |
| JP2022508651A (ja) * | 2018-10-08 | 2022-01-19 | レヴォリューション・メディスンズ，インコーポレイテッド | 癌を処置するためのｓｈｐ２阻害剤組成物および方法 |
| MX2021009562A (es) | 2019-02-12 | 2021-09-08 | Novartis Ag | Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1. |
| CN111647000B (zh) * | 2019-03-04 | 2021-10-12 | 勤浩医药（苏州）有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
| CN114502165A (zh) | 2019-09-23 | 2022-05-13 | 苏州浦合医药科技有限公司 | Shp2抑制剂及其用途 |
-
2022
- 2022-05-04 IL IL308222A patent/IL308222A/en unknown
- 2022-05-04 US US17/736,879 patent/US12097203B2/en active Active
- 2022-05-04 CA CA3217084A patent/CA3217084A1/en active Pending
- 2022-05-04 JP JP2023567924A patent/JP2024516037A/ja active Pending
- 2022-05-04 EP EP22799520.6A patent/EP4334318A4/en not_active Withdrawn
- 2022-05-04 AU AU2022271243A patent/AU2022271243A1/en active Pending
- 2022-05-04 WO PCT/US2022/027696 patent/WO2022235817A1/en not_active Ceased
- 2022-05-04 MX MX2023013064A patent/MX2023013064A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US12097203B2 (en) | 2024-09-24 |
| US20220370457A1 (en) | 2022-11-24 |
| EP4334318A1 (en) | 2024-03-13 |
| IL308222A (en) | 2024-01-01 |
| AU2022271243A1 (en) | 2023-11-30 |
| JP2024516037A (ja) | 2024-04-11 |
| WO2022235817A1 (en) | 2022-11-10 |
| EP4334318A4 (en) | 2025-03-05 |
| CA3217084A1 (en) | 2022-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024009727A (es) | Terapias de combinacion. | |
| MX2025003398A (es) | Nuevo compuesto tetraheterociclico | |
| EP4234030A3 (en) | Pd-1/pd-l1 inhibitors | |
| CR20240059A (es) | Compuestos tricíclicos como inhibidores de kras. | |
| EP4249000A3 (en) | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor | |
| PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
| AU2018238202A8 (en) | Combination therapy for the treatment or prevention of tumours | |
| AU2020281332A8 (en) | Dna-dependent protein kinase inhibitor | |
| MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| PH12023552079A1 (en) | Cdk2 inhibitors and methods of using the same | |
| MX2023013064A (es) | Terapias combinadas que comprenden inhibidores de shp2 e inhibidores de pd-1. | |
| EP4497438A3 (en) | Tricyclic parp1 inhibitors and uses thereof | |
| TN2010000204A1 (en) | Kinesin inhibitors as cancer therapeutics | |
| WO2021142448A3 (en) | Tgf-beta inhibitors and use thereof | |
| MX2025010157A (es) | Metodo de preparacion y uso de un derivado de dihidrotienopirimidina | |
| MX2024004213A (es) | Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados. | |
| PH12022551052A1 (en) | Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor | |
| WO2022240971A3 (en) | Kras g12d inhibitors and uses thereof | |
| MX2025007384A (es) | Inhibidores de malt1 | |
| MX2023004342A (es) | Politerapia de antagonistas de union al eje de pd-1 e inhibidores de lrrk2. | |
| WO2024026483A3 (en) | Cdk2 inhibitors and methods of using the same | |
| WO2024026486A3 (en) | Cdk2 inhibitors and methods of using the same | |
| WO2024026479A3 (en) | Cdk2 inhibitors and methods of using the same | |
| WO2023055885A3 (en) | Ezh2 inhibition in pancreatic cancer | |
| MX2023005530A (es) | Metodos y composiciones que comprenden un inhibidor de krasg12c y un antagonista de union a pd-l1 para tratar cancer de pulmon. |